Skip to Main content Skip to Navigation
New interface
Journal articles

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study

François Bertucci 1 Mahmoud Fekih Aurélie Autret 2 Thierry Petit 3 Florence Dalenc 4 Christelle Levy 5 Gilles Romieu 6 Jacques Bonneterre 7 Jean-Marc Ferrero 8 Pierre Kerbrat 9 Patrick Soulie 10 Marie-Ange Mouret-Reynier 11 Thomas Bachelot 12 Florence Lerebours 13 Jean-Christophe Eymard 14 Mathilde Deblock 15 Alain Lortholary 16 Anne-Claire Hardy-Bessard 17 Philippe Barthelemy 18 Hervé Bonnefoi 19 Emmanuelle Charafe-Jauffret François-Clément Bidard Patrice Viens Jérôme Lemonnier Jean-Yves Pierga 
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03623735
Contributor : François Bertucci Connect in order to contact the contributor
Submitted on : Tuesday, March 29, 2022 - 6:50:53 PM
Last modification on : Tuesday, November 22, 2022 - 2:26:16 PM

Identifiers

Citation

François Bertucci, Mahmoud Fekih, Aurélie Autret, Thierry Petit, Florence Dalenc, et al.. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncology, 2016, 17 (5), pp.600-611. ⟨10.1016/s1470-2045(16)00011-5⟩. ⟨hal-03623735⟩

Share

Metrics

Record views

18